Teva Pharmaceutical Industries Ltd (NYSE:TEVA) announced today that it had launched a generic version of Viagra® (sildenafil) immediately on patent expiry in Germany, the United Kingdom, Italy, the Netherlands, Switzerland, Ireland, Austria, Belgium and Denmark. The company had already launched the product in Spain, Canada and certain other countries. Dipankar Bhattacharjee, President and CEO Europe Generics, welcomed the launch: “Teva has a proud track record of bringing high-quality generics to the market on day one of patent expiry, and we have been able to launch sildenafil immediately on patent expiry in all the major markets of Europe. The launch today of sildenafil will bring choice to the pharmacy to help them serve the patient, and to help ensure that high-quality healthcare in Europe is affordable.” Teva is supplying the market via its existing wholesaler and pharmacy channels and will not, in line with European legislation, offer the product directly to consumers. About sildenafil and erectile dysfunction (ED) Sildenafil is used to treat erectile dysfunction in adult men. In the natural setting, i.e. with sexual stimulation, it restores impaired erectile function by increasing blood flow to the penis. Erectile dysfunction or ED is the inability to achieve or maintain a penile erection sufficient for satisfactory sexual performance. Problems with erections may be related to a wide variety of factors. In approximately half of men ED is age-related problem, but very often it can be associated with chronic illness like atherosclerosis and diabetes, or psychiatric illness like depression. It may also occur in men with other chronic illnesses like chronic heart failure, hepatic failure, multiple sclerosis, Alzheimer disease, chronic obstructive pulmonary disease. Men with endocrine disorders, such as hypogonadism, hyperprolactinaemia, and hypo- or hyper-thyroidism are also at greater risk. Problems with erections may also stem from medications, drinking too much alcohol, or tiredness.